Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Complete title: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: (see comment for full title)

Research Study Number ENCIT-01
 
Principal Investigator Julie Park, MD
 
Phase I

Research Study Description

Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the investigators are attempting to use T cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR). The CAR enables the T cell to recognize and kill the neuroblastoma cell through the recognition of CD171, a protein expressed of the surface of the neuroblastoma cell in patients with neuroblastoma. This is a phase 1 study designed to determine the maximum tolerated dose of the CAR+ T cells.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ENCIT-01
 
Contact Immunotherapy Study Line
 
Telephone 206/987-2553
 
E-mail
 

Keywords: Pediatric Cancers, Miscellaneous; Neuroblastoma; Neuroectodermal Tumors, Primitive (PNET); Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors; Ganglioneuroblastoma; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials